Temsirolimus is an i.v. administered inhibitor of mammalian target of rapamycin with activity in the first-line setting in poor-prognosis patients with metastatic renal cell carcinoma (RCC). The efficacy of this agent after failure of prior inhibitors of vascular endothelial growth factor (VEGF) is unknown.
background
The treatment of metastatic renal cell carcinoma (RCC) has advanced greatly in recent years. Several agents, including sunitinib, sorafenib, temsirolimus, and bevacizumab, have shown benefits in large randomized trials [1] [2] [3] [4] . The previous standard of therapy, interferon, has been largely supplanted by the newer agents, which are either inhibitors of vascular endothelial growth factor (VEGF; sunitinib, sorafenib and bevacizumab) or inhibitors of mammalian target of rapamycin (mTOR) (temsirolimus).
Clinicians treating metastatic RCC are now faced with a relatively new challenge of therapeutic choice after failure of first-line treatment. Only one prospective randomized trial has been published, which addresses this situation. In this trial, patients with metastatic RCC who had progressed on initial treatment with sunitinib, sorafenib or both were randomized to receive either everolimus (an oral inhibitor of mTOR) or placebo. The trial was terminated after the second interim analysis indicated a significant difference in disease progression, favoring the everolimus arm [5] .
Limited data have been publicized on the sequential use of different inhibitors of VEGF. Sunitinib has been shown in a prospective trial to have antitumor activity in bevacizumabrefractory metastatic RCC, with a response rate of 23% and median progression-free survival of 30.4 weeks [6] . Likewise, axitinib has been associated with a response rate of 23% and a progression-free survival of 7.4 months in sorafenibrefractory metastatic RCC [7] .
In poor-prognosis patients, in the first-line setting, temsirolimus is associated with a longer overall survival and progression-free survival than interferon [3] . The efficacy of temsirolimus in the second-line setting is unclear. Two abstracts have previously been presented describing the response to temsirolimus after failure of initial therapy. Bojanapally et al. have presented their experience with compassionate versus commercial use of temsirolimus in patients who had received prior systemic therapy. The median survival was between 2.5 and 4 months, and patients who had received fewer prior therapies had longer survival [8] . Schmidinger et al. [9] All patients were at least 18 years of age and had a histologically confirmed diagnosis of RCC. All histologic subtypes of RCC were included. Radiologic response was assessed using the Response Evaluation Criteria in Solid Tumors [10] , although central radiologic review was not carried out.
Data collected included demographic characteristics, toxic effects while on treatment and response outcomes. Data were managed using Microsoft ACCENT database software. With respect to toxic effects, data regarding serious adverse events, hyperglycemia and pneumonitis were retrospectively collected through review of both paper and electronic patient records. A serious adverse event was defined as having occurred after at least one dose of temsirolimus and causing death, a life-threatening medical event, hospitalization or prolongation of existing hospitalization. Time to progression (TTP) and overall survival were calculated with SAS software version 9.2, according to the Kaplan-Meier method. In total, 87 patients who received treatment with temsirolimus after having progression on a VEGF were identified. The demographic characteristics are detailed in Table 1 . Median age of the group was 63, and 66% were male. Eastern Cooperative Oncology Group (ECOG) performance status ranged from zero to three, and most patients were in the intermediate prognosis group of the Memorial Sloan Kettering classification scheme [11] .
Treatments given before temsirolimus are noted in Table 2 . The mean number of therapies before temsirolimus was 1.7. The mean number of inhibitors of VEGFs (including sunitinib, sorafenib, bevacizumab and AZD2171) was 1.4. All patients must have received therapy with at least one inhibitor of VEGF to be considered in this analysis. In most patients, a starting dose of 25 mg temsirolimus i.v. once weekly was used.
toxic effects
Due to the retrospective nature of this review, data were gathered only for serious adverse events, hyperglycemia and noninfectious pneumonitis. A serious adverse event was defined as having occurred after at least one dose of temsirolimus and causing death, a life-threatening medical event, hospitalization or prolongation of existing hospitalization.
Serious adverse events requiring admission to hospital included noninfectious pneumonitis (three patients), All patients received at least one vascular endothelial growth factor-directed therapy before temsirolimus.
original article Annals of Oncology congestive heart failure (one patient), confusion (one patient), hyperkalemia with elevated creatinine (one patient), ascites (one patient) central nervous system infection (one patient), duodenal perforation with death (one patient) and intussusceptions requiring surgery (one patient). Four patients were admitted to the hospital with sequelae of progressive metastatic RCC. One patient had temsirolimus discontinued for a grade 4 rash (one patient). Non-infectious pneumonitis was observed in nine patients (10%), the majority of whom displayed radiologic changes only (ground glass opacities on computed tomography without associated symptoms). Three patients with pneumonitis required admission to the hospital for investigations (e.g. bronchoscopy) and supportive care. No patients required mechanical ventilation.
Hyperglycemia occurred in 27% of patients de novo, while 6% of patients with preexisting diabetes experienced a worsening of glycemic control.
efficacy
The radiologic response rate (as assessed by the investigators, with no central radiologic review) is noted in Table 3 . Ten patients were not assessable for radiologic response due to either early treatment discontinuation (<3 weeks) or patient refusal of subsequent imaging. Of the 77 assessable patients, no complete responses were seen. Partial responses were observed in 5% of patients, and stable disease was observed in 65%, for a total disease control rate of 70%. Among those patients with nonclear cell histology (papillary and chromophobe), the response rate was 9% and stable disease rate was 72%.
The median TTP (using the method of Kaplan-Meier with progression as the failure point) on temsirolimus was 119 days [3.9 months, 95% confidence interval (CI) 2.8-4.8 months]. Median overall survival was 11.2 months.
For patients in the poor-prognosis group, the median TTP was 2.6 months (95% CI 1.2-3.9 months). For patients in the intermediate and favorable prognostic group, the median TTP was 4.8 months (95% CI 3.2-5.7 months).
There was no significant difference in the TTP between patients who had received more than one VEGF inhibitor before temsirolimus and those who received only one VEGF inhibitor (3.73 versus 3.97 months).
discussion
Temsirolimus has been shown previously to prolong survival compared with interferon in poor-prognosis patients with metastatic RCC in the first-line setting [3] . Here, we describe the outcome of patients with metastatic RCC who were treated with temsirolimus after failure of at least one inhibitor of VEGF.
An oral inhibitor of mTOR, everolimus, has been recently shown to prolong progression-free survival in metastatic RCC [5] after progression on sunitinib, sorafenib or both. In comparing our outcomes with those seen on the everolimus trial, we note that the patients in our series should have been expected to fare worse than those on the everolimus trial, according to the distribution of patients in the Memorial Sloan Kettering Cancer Centre prognostic groups. In the everolimus trial, 15% of patients were in the poor-prognosis group, whereas 36% of our patients were in the poor-prognosis group. Likewise, 29% of patients in the everolimus trial were in the favorable prognosis group, and 2% of patients in our series were in the favorable group. Our patients were heavily pretreated and of a worse functional status (our group included ECOG 3 patients, while the everolimus trial excluded patients with Karnofsky performance status worse than 70%).
Despite the less favorable initial prognosis of our cohort of patients, our rates of radiologic response and disease stabilization were comparable with those seen on the everolimus trial. The disease control rate (response + stable disease) in the everolimus trial was 64% and in our group of patients the disease control rate was 70%. Likewise, our progression-free survival time of 3.9 months and that seen in the everolimus trial was 4.0 months.
Patients in the poor-prognosis group had a shorter TTP than the overall group of 87 patients, thus confirming the validity of the prognostic categorization even in the treatment-refractory setting. The 2.6-month TTP is predictably shorter than the 3.8-month progression-free survival seen in the large, prospective first-line trial of temsirolimus [3] . The degree of pre-treatment (i.e. one versus more than one VEGF inhibitor) had no impact on the TTP.
In terms of toxicity, the rate of hyperglycemia in our patients was 32% (this includes both patients with no prior history of hyperglycemia and those with a worsening of preexisting diabetes). On the everolimus trial, 50% of patients experienced some degree of hyperglycemia. For noninfectious pneumonitis, our rate was 11% compared with 8% in the everolimus trial.
It should also be noted that our trial did not exclude patients with nonclear cell histology, as was the case in the everolimus trial. In the nonclear cell population, the disease control rate was 81%. The previously published first-line trial of temsirolimus also suggested some benefit in the nonclear cell population [3, 12] .
The limitations on the quality of data in our review should be noted. The patient population was somewhat heterogeneous, and no central review of radiology was carried out; this lack of central review leaves the progression-free survival result vulnerable to bias. Furthermore, this was a retrospective review of a fairly small group of patients (N = 87). It still, however, represents the largest series to date of patients with metastatic renal cancer who received temsirolimus after failure of a VEGF-directed therapy.
conclusions
We report the outcome of patients on the Temsirolimus Compassionate Use Program at four cancer centers in Ontario, Canada and Ohio. The disease control rate was 70%, and median TTP was 3.9 months. Efficacy is comparable with that in a large prospective trial with everolimus [5] , despite the fact that the Torisel Compassionate Use Program patients had a worse prognosis by MSKCC criteria [11] . A more comprehensive assessment of the efficacy of temsirolimus in the second-line setting will be available with the results of the ongoing clinical trial comparing temsirolimus with sorafenib after progression of metastatic RCC on sunitinib.
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